TY - JOUR
T1 - Resolution of cochlear inflammation
T2 - Novel target for preventing or ameliorating drug-, noise- and age-related hearing Losss
AU - Kalinec, Gilda M.
AU - Lomberk, Gwen
AU - Urrutia, Raul A.
AU - Kalinec, Federico
N1 - Funding Information:
This work was supported by the National Institutes of Health (grant DK52913), the Department of Head and Neck Surgery, David Geffen School of Medicine at UCLA and Mayo Foundation funds. The content of this work is solely the responsibility of the authors and does not necessarily represent the official views of these Institutions.
Publisher Copyright:
© 2017, Frontiers Media S.A. All rights reserved.
PY - 2017/7/7
Y1 - 2017/7/7
N2 - A significant number of studies support the idea that inflammatory responses are intimately associated with drug-, noise-and age-related hearing loss (DRHL, NRHL and ARHL). Consequently, several clinical strategies aimed at reducing auditory dysfunction by preventing inflammation are currently under intense scrutiny. Inflammation, however, is a normal adaptive response aimed at restoring tissue functionality and homeostasis after infection, tissue injury and even stress under sterile conditions, and suppressing it could have unintended negative consequences. Therefore, an appropriate approach to prevent or ameliorate DRHL, NRHL and ARHL should involve improving the resolution of the inflammatory process in the cochlea rather than inhibiting this phenomenon. The resolution of inflammation is not a passive response but rather an active, highly controlled and coordinated process. Inflammation by itself produces specialized pro-resolving mediators with critical functions, including essential fatty acid derivatives (lipoxins, resolvins, protectins and maresins), proteins and peptides such as annexin A1 and galectins, purines (adenosine), gaseous mediators (NO, H2S and CO), as well as neuromodulators like acetylcholine and netrin-1. In this review article, we describe recent advances in the understanding of the resolution phase of inflammation and highlight therapeutic strategies that might be useful in preventing inflammation-induced cochlear damage. In particular, we emphasize beneficial approaches that have been tested in pre-clinical models of inflammatory responses induced by recognized ototoxic drugs such as cisplatin and aminoglycoside antibiotics. Since these studies suggest that improving the resolution process could be useful for the prevention of inflammationassociated diseases in humans, we discuss the potential application of similar strategies to prevent or mitigate DRHL, NRHL and ARHL.
AB - A significant number of studies support the idea that inflammatory responses are intimately associated with drug-, noise-and age-related hearing loss (DRHL, NRHL and ARHL). Consequently, several clinical strategies aimed at reducing auditory dysfunction by preventing inflammation are currently under intense scrutiny. Inflammation, however, is a normal adaptive response aimed at restoring tissue functionality and homeostasis after infection, tissue injury and even stress under sterile conditions, and suppressing it could have unintended negative consequences. Therefore, an appropriate approach to prevent or ameliorate DRHL, NRHL and ARHL should involve improving the resolution of the inflammatory process in the cochlea rather than inhibiting this phenomenon. The resolution of inflammation is not a passive response but rather an active, highly controlled and coordinated process. Inflammation by itself produces specialized pro-resolving mediators with critical functions, including essential fatty acid derivatives (lipoxins, resolvins, protectins and maresins), proteins and peptides such as annexin A1 and galectins, purines (adenosine), gaseous mediators (NO, H2S and CO), as well as neuromodulators like acetylcholine and netrin-1. In this review article, we describe recent advances in the understanding of the resolution phase of inflammation and highlight therapeutic strategies that might be useful in preventing inflammation-induced cochlear damage. In particular, we emphasize beneficial approaches that have been tested in pre-clinical models of inflammatory responses induced by recognized ototoxic drugs such as cisplatin and aminoglycoside antibiotics. Since these studies suggest that improving the resolution process could be useful for the prevention of inflammationassociated diseases in humans, we discuss the potential application of similar strategies to prevent or mitigate DRHL, NRHL and ARHL.
KW - Age-related hearing loss
KW - Annexin A1
KW - Drug-induced hearing loss
KW - Galectin
KW - Inflammation
KW - Lipid mediators
KW - Noise-induced hearing loss
KW - Resolution of inflammation
UR - http://www.scopus.com/inward/record.url?scp=85026658590&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85026658590&partnerID=8YFLogxK
U2 - 10.3389/fncel.2017.00192
DO - 10.3389/fncel.2017.00192
M3 - Review article
AN - SCOPUS:85026658590
SN - 1662-5102
VL - 11
JO - Frontiers in Cellular Neuroscience
JF - Frontiers in Cellular Neuroscience
M1 - 192
ER -